Pestronk Lab

Alan Pestronk, MD

Research interests: Neuromuscular disorders

Clinical interests: Clinical neurology, neuromuscular disease, neuroimmunology, glycolipids, proteoglycans, aging and the nervous system, history of neurology, myopathy, neuropathy, weakness, myasthenia, muscle, nerve, numbness, sensory loss, pain, fatigue, muscular dystrophy, neuro muscular.

Learn more on the Neuromuscular Disease Center website »

Principal investigator

Alan Pestronk, MD

Professor, Neurology
Section Chief, Neuromuscular Diseases
Professor, Pathology
Director, Neuromuscular Clinical Laboratory

Recent publications

  • Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophyStatland, J. M., Campbell, C., Desai, U., Karam, C., Díaz-Manera, J., Guptill, J. T., Korngut, L., Genge, A., Tawil, R. N., Elman, L., Joyce, N. C., Wagner, K. R., Manousakis, G., Amato, A. A., Butterfield, R. J., Shieh, P. B., Wicklund, M., Gamez, J., Bodkin, C., Pestronk, A., & 9 othersWeihl, C. C., Vilchez-Padilla, J. J., Johnson, N. E., Mathews, K. D., Miller, B., Leneus, A., Fowler, M., van de Rijn, M. & Attie, K. M., Jul 2022, In: Muscle and Nerve. 66, 1, p. 50-62 13 p.Research […]
  • Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseaseThomas, F. P., Brannagan, T. H., Butterfield, R. J., Desai, U., Habib, A. A., Herrmann, D. N., Eichinger, K. J., Johnson, N. E., Karam, C., Pestronk, A., Quinn, C., Shy, M. E., Statland, J. M., Subramony, S. H., Walk, D., Stevens-Favorite, K., Miller, B., Leneus, A., Fowler, M., Van De Rijn, M., & 1 othersAttie, K. M., Jun 7 2022, In: Neurology. 98, 23, p. E2356-E2367Research output: Contribution to journal › Article › peer-review
  • Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal studyThe Jain COS Consortium, May 2022, In: Muscle and Nerve. 65, 5, p. 531-540 10 p.Research output: Contribution to journal › Article › peer-review
  • Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis ApproachMayhew, A. G., James, M. K., Moore, U., Sutherland, H., Jacobs, M., Feng, J., Lowes, L. P., Alfano, L. N., Muni Lofra, R., Rufibach, L. E., Rose, K., Duong, T., Bello, L., Pedrosa-Hernández, I., Holsten, S., Sakamoto, C., Canal, A., Sánchez-Aguilera Práxedes, N., Thiele, S., Siener, C., & 25 othersVandevelde, B., DeWolf, B., Maron, E., Gordish-Dressman, H., Hilsden, H., Guglieri, M., Hogrel, J. Y., Blamire, A. M., Carlier, P. G., Spuler, S., Day, J. W., Jones, K. J., Bharucha-Goebel, D. X., Salort-Campana, E., Pestronk, […]
  • Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophythe Cooperative International Neuromuscular Research Group investigators and Duchenne Regulatory Science Consortium members, Mar 2022, In: CPT: Pharmacometrics and Systems Pharmacology. 11, 3, p. 318-332 15 p.Research output: Contribution to journal › Article › peer-review